Abstract:Objective To compare the efficacy and safety of different drugs in children with mild pneumonia so as to provide clinical reference for the choice of drug in the treatment. Methods Ninety patients with mild pneumonia treated in Nanjing Jiangbei Hospital from January 2020 to March 2021 were selected as the research objects and were randomly divided into three groups: ceftizoxime alone group (control group 1, n=30), ceftizoxime plus azithromycin for suspension group (control group 2, n=30) and ceftizoxime plus erythromycin cyclocarbonate for suspension group (experiment group, n=30). The treatment effect, the time when clinical symptoms subsided (temperature recovered, cough disappeared or significantly improved, lung dry and moist rales disappeared) and the incidence of adverse reactions were compared and analyzed among three groups. Results There was significant difference in the curative effect among the three groups （χ²=13.711, P=0.008), and that of the experiment group was the best. There was no significant difference in hospital stay, improvement of cough and disappearance time of lung dry and moist rales among three groups (P>0.05). Compared with control group 1 and control group 2, the temperature recovery time was prolonged in experiment group (P<0.05). The adverse reaction rate of experiment group (10.00%) was similar to that of control group 1 (6.67%) treated with ceftizoxime alone, which was slightly lower than that of control group 2 (26.67%), but the difference was not significant (P>0.05). Conclusion In the treatment of children with mild pneumonia, erythromycin cyclocarbonate for suspension has similar curative effect as azithromycin for suspension, with lower incidence of adverse reactions and is beneficial to improve the treatment compliance of children.